secwatch.observer — SEC 8-K summary
======================================

Issuer:     Biohaven Ltd. (BHVN)
CIK:        0001935979
Form:       8-K
Filed at:   2026-03-02T23:59:59+00:00
Accession:  0001935979-26-000022
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biohaven reports Q4 loss $145.6M, prioritizes three late-stage programs, raises $178.9M
--------------------------------------------------------------------------------

- Q4 net loss $145.6M ($1.21/sh); non-GAAP adj. net loss $107.9M ($0.90/sh).
- Cash, equivalents, securities $322M at year end; raised $178.9M via 17.2M share issuance.
- Pivotal trial for IgAN degrader BHV-1400 starts Q1 2026; Graves' degrader BHV-1300 pivotal in 2H 2026.
- Opakalim OLE: >50% seizure reduction in most on 75mg at 6 months; pivotal data due 2H 2026.
- Taldefgrobep Phase 2 obesity initiated Q4 2025; topline results expected 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000022/0001935979-26-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1935979/000193597926000022/bhvn-20260302.htm
  HTML page:      https://secwatch.observer/filing/0001935979-26-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer